• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns

by MM360 Staff | Jul 19, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma

by MM360 Staff | Jul 18, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

by MM360 Staff | Jul 17, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis

by MM360 Staff | Jul 17, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy

by MM360 Staff | Jul 15, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Incidence and prevalence of light chain amyloidosis in the United States in 2019–2021 using Optum EHR data

by MM360 Staff | Jul 12, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
  • Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
  • Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus
  • Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma
  • Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT